Unknown OBSERVATIONAL NCT05055531

Effects of the Vaccin Against COVID 19 in a Cohort of Dialysis Patients: Adverse Events and Immunological Response (VACOVEIRI)

Sponsor: Raincy Montfermeil Hospital Group

Updated 6 times since 2021 Last updated: Apr 29, 2022 Started: Aug 8, 2021 Primary completion: Jun 30, 2023 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates COVID Epidemic and is currently ongoing. Raincy Montfermeil Hospital Group leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Mar 2024 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jun 2022 — Mar 2024 [monthly]

Recruiting
Apr 2022 — Jun 2022 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Oct 2021 — Apr 2022 [monthly]

Not Yet Recruiting

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Raincy Montfermeil Hospital Group

Data source: Raincy Montfermeil Hospital Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreuil, France